MDNA Life Sciences (PRIVATE: MDNALIFE) Stock Information | RedChip

 :  logo small-cap

MDNA Life Sciences

 Company Website

MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.


Investor Presentation

Investor Presentation

  • Molecular diagnostic platform company exploiting the biological advantages of mitochondrial DNA (mtDNA)
  • Non invasive, blood based, liquid biopsy format to detect disease
  • Unmatched rapid, agile development of proprietary diagnostic tests
  • Two product candidates in development for early disease detection, eight more in pipeline
    • Prostate cancer detection Mitomic ™Prostate Test (MPT™)
    • Endometriosis detection Mitomic ™Endometriosis Test (MET™)
  • Two analytical studies completed for biomarkers related to MPT ™and MET ™ three more planned in 2023 for CE IVD approval
  • Licensed our IP related to the MPT ™biomarker with Laboratory Corporation of America Holdings

*By entering your information you agree to our privacy policy.